Healthcare Equipment and Supplies
Company Overview of Svelte Medical Systems, Inc.
Svelte Medical Systems, Inc. designs and develops balloon expandable stents for the treatment of atherosclerosis. It develops an integrated delivery system that navigates coronary arteries like a guide wire, as well as simplifies the stenting procedure. The company also develops drug-eluting stents. Its markets its products in the European Union; and selected South American countries, such as Brazil. Svelte Medical Systems, Inc. was founded in 2007 and is based in New Providence, New Jersey.
675 Central Avenue
New Providence, NJ 07974
Founded in 2007
Key Executives for Svelte Medical Systems, Inc.
Chief Executive Officer, President and Director
Vice President of Quality Assurance
European Business Director
Vice President of Operations
Compensation as of Fiscal Year 2015.
Svelte Medical Systems, Inc. Key Developments
Svelte Medical Systems Reports Updates to Clinical Program
May 26 15
Svelte Medical Systems reported 1-year clinical results from the DIRECT II study were similar to those seen at 6-months, with non-inferiority clearly established. The company announced that target Lesion Failure (TLF), a primary clinical indicator of device efficacy, increased from 2.8% at 6-months to 3.7 % at 1-year in the Svelte arm, while TLF in the control arm reached 7.8% at the same 1-year time point. The Svelte arm also exhibited reduced procedure and device times, with trends toward reduced fluoroscopy time and contrast use compared with the control arm, confirming results observed in prior studies utilizing Svelte technologies. DIRECT II is a prospective, randomized, multi-center clinical study comparing the safety and efficacy of the Svelte drug-eluting coronary stent-on-a-wire Integrated Delivery System (IDS) and the Medtronic Resolute Integrity drug-eluting coronary stent in 159 patients undertaken in support of CE Mark certification of the Svelte IDS. Utilizing a fixed-wire design which provides the lowest crimped stent profile on the market, proprietary balloon technology for direct stenting and a new class of bioresorbable drug coating, the IDS is designed to optimize trans-radial interventions (TRI) and a 'slender' approach to PCI by downsizing catheter sizes used during intervention.
Svelte Medical Systems, Inc. Welcomes Richard Dakers to Board of Directors
Mar 19 15
Svelte Medical Systems, Inc. welcomed Richard Dakers of the Gary and Mary West Health Investment Fund to its board of directors.
Svelte Medical Systems and Asahi Intecc USA Sign Manufacturing and Co-Branding Deal
Feb 17 15
Svelte Medical Systems and Asahi Intecc reported that Svelte and Asahi Intecc USA., a subsidiary company of Asahi Intecc, executed formal agreements relating to the manufacture and co-branding of the Svelte drug-eluting coronary stent fixed wire Integrated Delivery System (IDS). The collaboration will feature ASAHI's ACTONE wire technology in the design, development and supply of core wire and coil assemblies for the Svelte IDS.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries